Jacobs Engineering Group Inc. (NYSE:JEC) reported its results for the fourth quarter. Net income for Jacobs Engineering Group Inc. rose to $94.3 million (74 cents per share) vs. $77 million (61 cents per share) in the same quarter a year earlier. This marks a rise of 22.5% from the year earlier quarter. Revenue rose 15.2% to $2.7 billion from the year earlier quarter. JEC beat the mean analyst estimate of 73 cents per share. It fell short of the average revenue estimate of $2.77 billion.
Jacobs Chief Financial Officer John W. Prosser, Jr. stated, “With a solid backlog and improving prospects as we finish 2011, we are initiating guidance for fiscal 2012 earnings per share within a range of $2.80 to $3.20.”
Competitors to Watch: Fluor Corporation (NYSE:FLR), URS Corporation (NYSE:URS), The Shaw Group Inc. (NYSE:SHAW), Tetra Tech, Inc. (NASDAQ:TTEK), KBR, Inc. (NYSE:KBR), Michael Baker Corporation (AMEX:BKR), AECOM Technology Corp. (NYSE:ACM), Granite Construction Inc. (NYSE:GVA), Willdan Group, Inc. (NASDAQ:WLDN), and Quanta Services, Inc. (NYSE:PWR).
Covidien plc (NYSE:COV) reported its results for the fourth quarter. Net income for Covidien plc rose to $451 million (93 cents per share) vs. $443 million (77 cents per share) in the same quarter a year earlier. This marks a rise of 1.8% from the year earlier quarter. Revenue rose 15.4% to $3.08 billion from the year earlier quarter. COV reported adjusted net income of $1.08 per share. By that measure, the company beat the mean estimate of $1.05 per share. Analysts were expecting revenue of $3.03 billion.
“We delivered strong fourth-quarter and fiscal 2011 results,” said Jos E. Almeida, President and CEO. “This performance was aided by successful new product launches, market share gains in several key categories and exceptional commercial execution. We significantly increased R&D spending, made other important growth-driving investments and again generated strong cash flow. Looking to 2012, we remain comfortable with the sales and operating margin guidance we issued in September. Although the market environment continues to be challenging, our expectations for the operational growth of our business have not changed. We are confident that our robust new products pipeline, skilled workforce and strategic investments in emerging markets will drive positive operational results in 2012 and beyond.”
Competitors to Watch: C.R. Bard, Inc. (NYSE:BCR), Teleflex Incorporated (NYSE:TFX), Becton, Dickinson and Co. (NYSE:BDX), Baxter International Inc. (NYSE:BAX), Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI), CareFusion Corporation (NYSE:CFN), CONMED Corporation (NASDAQ:CNMD), AngioDynamics, Inc. (NASDAQ:ANGO), and Masimo Corporation (NASDAQ:MASI).